TVTX · Travere Therapeutics, Inc.

The thesis

Travere Therapeutics' kidney drug FILSPARI is still in a fast launch, but the shares have slid into the third-quarter report and the company changes chief executive on 1 December 2026. The report, which Travere announced on 27 October 2026 and which is estimated for about 3 November, decides the case: FILSPARI US net sales need to top the second quarter's $141.1 million, and new patient start forms need to top 2,012.

The shares closed at $50.88 on 27 October 2026, 24.6% below the 52-week high of $67.52. The three-month price change was a decline of 11.2%, and the 14-day relative strength index (RSI), a momentum gauge on which readings under 30 mark heavy selling, was 40.5. The close on 14 October was $53.27 with an RSI of 27.5, so the stock has made a new low while the RSI has recovered.

The narrative is maturing: the launch is well known, and the analyst target raises of 22 September–24 did not stop the decline. New clinical data presented at the American Society of Nephrology Kidney Week on 23 October–24 did not change the revenue question that the report settles. The rating stays where it was, because the only new fact is data that supports the drug's biology rather than its sales.

Bullish and bearish views on Travere Therapeutics, Inc.

The bull case on Travere Therapeutics, Inc. (TVTX), in brief: Launch growth has a clear benchmark. The bear case: The shares keep falling.

Bull case

• Launch growth has a clear benchmark. Travere reported Q2 2026 FILSPARI US net sales of $141.1 million on 4 August, up 96% from a year earlier, with 2,012 new patient start forms.
• FSGS has no approved competitor. FILSPARI's focal segmental glomerulosclerosis (FSGS) indication is the first approved medicine for that kidney disease, per Travere's Q2 2026 release. Q3 2026 is the first full quarter of that launch.
• New biomarker data support the drug's mechanism. On 23 October–24, 2026, Travere presented PROTECT trial biomarker data at ASN Kidney Week. The company said FILSPARI cut markers of kidney inflammation and injury more than maximum-dose irbesartan in IgA nephropathy (IgAN) patients.
• Patent coverage for FSGS extended. On 23 September 2026, Travere said the US Patent and Trademark Office had allowed a patent on methods of using FILSPARI in FSGS, with expected coverage into October 2037.
• Analysts hold targets far above the price. Guggenheim raised its target to $89 from $75 on 24 September 2026. Wedbush kept Outperform with a $76 target and HC Wainwright kept Buy with a $67 target, both on 22 September.

Bear case

• The shares keep falling. The close of $50.88 on 27 October compares with $53.27 on 14 October, $56.85 on 1 October and $62.76 on 18 September, all adjusted daily closes.
• A CEO handover lands mid-launch. Eric Dube steps down for health and family reasons, announced 21 September 2026. Bradley L. Campbell takes over 1 December, and the announcement carried no business update or guidance.
• Insiders sold shares. Dube's Form 4, filed 18 September 2026, records option exercises and sales on 15 September–17 under a Rule 10b5-1 trading plan adopted 16 June 2026.
• The company is still losing money. Travere reported a Q2 2026 net loss of $34.8 million under generally accepted accounting principles (GAAP), with a loss per share of $(0.37) against $(0.10) adjusted.
• IgAN competition is growing. Novartis's Fabhalta and Vera Therapeutics' atacicept compete for the IgAN patients who make up part of FILSPARI's sales.

Price setup

The shares closed at $50.88 on 27 October 2026, the lowest of the closes cited in this note and 24.6% below the 52-week high of $67.52. The next round-number level is $50, which is 1.7% below the last close.

Travere's $525 million of 0.50% convertible notes due 2032 carry an initial conversion price of about $64.90 per share, which sits above the current price.

Crowding evidence is limited. The report is imminent, and a CEO's pre-planned option sales in September are the one recent insider transaction on file. No share issuance has been reported since the last note, and the company has filed no new SEC documents in the period.

The view that the third-quarter report decides the direction would be wrong if the shares closed below $50 before the report and the quarter then showed sales above $141.1 million without a recovery.

Catalysts, next 30 days

• 1 December 2026 — Bradley L. Campbell becomes president and CEO. Outside the 30-day window, but any change to launch priorities or spending would surface around it.

Elapsed catalysts

• ~3 November 2026 (est.) — Q3 2026 financial results. Travere issued its date notice on 27 October 2026. Second-quarter notice came seven days before the 4 August report, which is the basis for the estimate. The report shows whether FILSPARI US sales beat $141.1 million and patient start forms beat 2,012. (passed 3d ago)

What would change the view

The commercial case breaks if Q3 2026 FILSPARI US net sales come in at or below $141.1 million, or new patient start forms at or below 2,012. A GAAP net loss wider than $34.8 million alongside flat or lower sales would add to it. Departures of commercial executives around the 1 December handover would also weaken it.

On price, a daily close below $50 would put the shares under the round-number level that the October note named and extend the decline from the September highs. A strong report would move the rating up. The first evidence would be sales well above the second quarter with start forms still rising.

What it trades with

Ligand Pharmaceuticals (LGND) holds a sparsentan royalty, so its royalty line gives an outside read on FILSPARI demand. Vera Therapeutics (VERA) and Novartis are the IgAN competitors whose launch updates bear on Travere's IgAN sales. The stock trades mainly on its own launch figures rather than with the broader biotech index.